The 4 most recent market catalysts affecting $RHHBY, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 17, 2026
Corporate Catalyst
Bullish
Impact 75
Roche Says Phase III CELESTIMO Study Meets Primary Endpoint With Clinically Meaningful Reduction In Disease Progression Risk For Follicular Lymphoma Patients
Roche announced that its Phase III CELESTIMO study, evaluating a Lunsumio-based regimen for follicular lymphoma, successfully met its primary endpoint at an interim analysis. This …
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 75
FDA Grants Priority Review To Genentech's Enspryng For MOGAD, Phase III METEOROID Study Showed 68% Reduction In Relapse Risk Versus Placebo
Genentech's Enspryng receiving FDA Priority Review for MOGAD is a significant development. This designation accelerates the review process for drugs that, if approved, would provid…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 65
Roche's Vabysmo Shows Sustained Two-Year Results In SALWEEN Study, With 61% Of PCV Patients Achieving Extended 20-Week Dosing
Roche announced positive two-year results from its SALWEEN study for Vabysmo, a drug treating polypoidal choroidal vasculopathy (PCV), an aggressive form of nAMD. The study showed …
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 75
FDA Grants Priority Review To Roche's Gazyva/Gazyvaro, Potential First Therapy For Primary Membranous Nephropathy, After Phase III MAJESTY Showed Superior Remission Versus Tacrolimus
Roche's Gazyva/Gazyvaro has been granted FDA Priority Review for primary membranous nephropathy (pMN), a chronic autoimmune disease with no currently approved therapies. This is a …
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.